查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718018

學名藥市場按產品類型、藥品類別、給藥途徑、患者類型、治療用途、分銷管道分類 - 全球預測 2025-2030

Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年學名藥市場規模將達到4,152.8億美元，2025年將成長至4,516.1億美元，複合年成長率為9.08%，到2030年將達到6,996.5億美元。

主要市場統計數據
基準年2024年 4152.8億美元
預計2025年 4516.1億美元
預測年份 2030 6996.5億美元
複合年成長率（%） 9.08%

學名藥市場正在經歷一段動態轉型期，受技術進步、監管改革和對具有成本效益的患者照護的重視的推動。本報告深入探討了創新與可負擔性融合以迎來下一波醫藥突破的市場格局。過去幾年，市場參與企業克服了嚴格的法規環境帶來的挑戰，同時平衡了對優質替代治療方案的需求。從製造商到醫療保健提供者的相關人員現在都專注於重新思考他們的策略，以利用已開發市場和新興市場中尚未開發的商業機會。

這一發展的背後是人們對學名藥的經濟和治療價值的認知不斷提高。製造商不斷努力改進生產流程、創新配方模板，並更快地將更安全、更有效的替代品推向市場。認知的提高、政策的支持以及對醫療保健可及性的強烈推動正在激發人們對學名藥的興趣，從而加速其成長軌跡並培育更健康的競爭格局。目前的市場環境要求我們不僅生產具有成本效益的藥物，還要提供科學合理的替代品，以更全面地滿足患者的需求。

這份綜合報告深入探討了市場區隔、區域趨勢、競爭基準化分析和策略建議等關鍵領域。本報告重點介紹了變革性變化和關鍵見解，以幫助決策者了解學名藥領域的機會和挑戰。隨著新技術和新治療需求塑造產業，本簡報為如何最好地應對未來市場情景的知情討論提供了一個平台。

變革性變化重新定義學名藥產業

學名藥領域正在經歷劇變，重新定義市場動態和競爭模式。技術進步、不斷發展的法規結構以及全球醫療保健政策的變化共同創造了一個以敏捷和創新為特徵的市場環境。製造業的快速數位化和自動化以及配方科學的突破不僅提高了業務效率，而且顯著縮短了生產週轉時間。此類技術干預使公司能夠滿足對高品質且價格合理的藥品不斷成長的需求，同時保持嚴格的安全標準，從而促進了市場的發展。

世界各地的監管機構正在採用更靈活和更具適應性的框架，鼓勵製造商在不影響品質的情況下加快產品平臺的開發。這些努力使公司能夠探索進入市場的替代途徑，並促進更快地獲得更多種類的學名藥。包括製造商、研究機構和政策制定者在內的各相關人員之間的合作進一步凸顯了這種適應性，這在解決全球製藥業固有的複雜問題方面發揮關鍵作用。

此外，個人化醫療的興起和慢性病的流行也刺激了對有效且經濟實惠的替代療法的需求。在必須快速適應新的醫療保健挑戰的生態系統中，該行業正在經歷向以患者為中心的方法的決定性轉變。與這些趨勢同時，採用數據分析和先進的市場研究技術使企業能夠即時了解消費行為和需求模式，從而改善其策略舉措。

目前正在進行的轉變顯然是多方面的、影響深遠的。背後的驅動力是需要解決民眾的成本敏感性以及滿足更廣泛的治療需求。因此，公司正在從傳統的基於數量的業務模式轉向更具創新性的、以品質為導向的模式。這種演變凸顯了一種更廣泛的趨勢，即先進技術與強力的監管支持的結合為學名藥市場的性能和創新樹立了新的基準。

學名藥市場的關鍵細分洞察

徹底的細分分析為了解影響學名藥市場的促進因素和障礙提供了寶貴的見解。首先，在評估產品類型時，我們透過區分非處方學名藥和處方學名藥來分析市場。這種細分使得市場參與者能夠根據客戶訪問動態和監管考慮來縮小他們的方法。除了按產品類型進行二分法評估外，還按藥物類別進行評估，包括鎮痛藥、抗生素、抗憂鬱症、抗糖尿病藥、抗組織胺和抗高血壓藥等治療物質。這些類別至關重要，因為它們反映了解決不同人群中普遍存在的健康問題的核心領域。

進一步細分，給藥途徑有複雜的考慮，例如吸入、注射、口服和外用。每種給藥途徑都有不同的臨床目標並滿足不同的患者需求，每種途徑在監管核准和市場滲透方面都面臨獨特的挑戰。透過詳細了解涵蓋成人、老年人和兒童人口統計的患者類型，可以進一步增強策略洞察力，突顯不同年齡層不斷變化的治療需求。這些見解使製造商和經銷商能夠客製化產品以滿足特定人口需求。

此外，治療應用在細分中起著至關重要的作用，因為市場可以透過抗感染藥感染疾病、心血管藥物、中樞神經系統（CNS）藥物、抗糖尿病藥物、腫瘤藥物、呼吸系統藥物等類別來觀察。深入了解這些治療領域不僅會突顯產品差異化，還會提高您的市場策略的相關性。最後，我們透過區分線下藥局和線上藥局來檢查分銷管道。線下部分進一步分為醫院藥房和零售藥房，每個部分都有不同的營運細節和市場動態。透過這種多層次的細分，可以識別並策略性地瞄準成長動力和潛在機會。

透過這種全面的細分，產業相關人員可以更清楚地了解消費行為、監管挑戰和競爭格局。分析強調，多方面的細分策略對於使產品開發、上市和分銷策略與學名藥領域的新興市場需求保持一致至關重要。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 政府採取優惠舉措，推廣學名藥的使用，以降低醫療成本
      • 生物相似藥投資增加推動學名藥市場成長
      • 慢性病盛行率上升推動了對可負擔且可獲得的藥物的需求
    • 限制因素
      • 對學名藥品質、功效和安全性的擔憂正在影響學名藥的採用
    • 機會
      • 藥品專利到期為學名藥上市創造巨大機會
      • 學名藥：透過藥品生產製程創新降低成本並提高質量
    • 任務
      • 嚴格的監管要求和核准時間對學名藥製造商構成挑戰
  • 市場區隔分析
    • 產品類型：消費者可近性和可負擔性推動了對非處方 (OTC)學名藥的需求
    • 藥物類別：增加抗憂鬱症的使用，以提高患者的依從性和治療效果
    • 給藥途徑：口服給藥，方便且病人接受度高
    • 病患類型：老年患者使用的錠劑和液體製劑學名藥
    • 治療應用：口服降血糖藥和胰島素學名藥的採用
    • 分銷管道：便利性和個人化服務是推動線下分銷通路偏好的因素
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章學名藥市場（依產品類型）

  • 非處方（OTC）學名藥
  • 處方箋學名藥

第7章學名藥市場（依藥品類別）

  • 止痛藥
  • 抗生素
  • 抗憂鬱症
  • 抗糖尿病藥物
  • 抗組織胺藥
  • 抗高血壓藥

第8章學名藥市場（依給藥途徑）

  • 吸入
  • 注射
  • 口服
  • 話題

第9章學名藥市場（依患者類型）

  • 對於成年人
  • 老年人
  • 小兒科

第 10 章學名藥市場（依治療應用）

  • 抗感染藥物
  • 心血管系統
  • 中樞神經系統（CNS）
  • 糖尿病
  • 腫瘤學
  • 呼吸系統

第11章學名藥市場（按分銷管道）

  • 離線
    • 醫院藥房
    • 零售藥局
  • 網路藥局

第 12 章：美洲學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章：亞太地區學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo, Inc.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC.
  • Intas Pharmaceuticals Ltd.
  • Krka, dd
  • Lupin Limited
  • Pfizer, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-F6513A06BE93

The Generic Drugs Market was valued at USD 415.28 billion in 2024 and is projected to grow to USD 451.61 billion in 2025, with a CAGR of 9.08%, reaching USD 699.65 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 415.28 billion
Estimated Year [2025] USD 451.61 billion
Forecast Year [2030] USD 699.65 billion
CAGR (%) 9.08%

The generic drugs market has witnessed an era of dynamic transformation, underpinned by advancements in technology, regulatory reforms, and an ever-increasing emphasis on cost-effective patient care. This report embarks on a detailed exploration of the market landscape where innovation meets affordability, driving the next wave of pharmaceutical breakthroughs. Over the past few years, market participants have navigated challenges from stringent regulatory environments while balancing the need for high-quality therapeutic alternatives. Stakeholders across the board-from manufacturers to healthcare providers-are now focusing on refining strategies to harness untapped opportunities in both developed and emerging markets.

Underpinning this progress is a growing recognition of the economic significance and therapeutic value of generic drugs. Manufacturers are continually striving to improve the production processes, innovate templates for drug formulations, and rapidly bring safe, efficacious alternatives to market. Increased awareness, policy support, and a robust drive towards making healthcare accessible are stimulating interest in generic drugs, thereby accelerating growth trajectories and fostering healthier competitive landscapes. The current market environment is not merely about producing cost-effective drugs; it is about delivering scientifically robust alternatives that meet patient demands more holistically.

In this comprehensive report, we dive deep into pivotal areas such as market segmentation, regional trends, competitive benchmarking, and strategic recommendations. The discussion elucidates transformative shifts and critical insights which help decision-makers understand both opportunities and challenges ahead in the generic drugs segment. As emerging technologies and novel therapeutic demands shape the industry, this brief sets the stage for an informed debate on how best to address future market scenarios.

Transformative Shifts Redefining the Generic Drugs Sector

The landscape of the generic drugs industry is undergoing seismic shifts that are redefining market dynamics and competitive paradigms. Technological advancements, evolving regulatory frameworks, and shifts in global healthcare policies are interweaving to create a market environment marked by agility and innovation. Rapid digitalization and automation in manufacturing, alongside breakthroughs in formulation science, have not only augmented operational efficiencies but also significantly reduced production turnaround times. These technological interventions have catalyzed the market by enabling firms to meet the soaring demand for high-quality yet affordable medicines, while simultaneously maintaining rigorous safety standards.

Regulatory bodies across the globe have adopted more flexible and adaptive frameworks, encouraging manufacturers to expedite their product pipelines without compromising on quality. Such initiatives have allowed companies to explore alternative routes to market, facilitating faster entry for a wider range of generic therapies. This adaptability is further highlighted by collaborations between various stakeholders-including manufacturers, research institutions, and policy-makers-which are instrumental in navigating the complexities inherent in the global pharmaceuticals arena.

Moreover, the rise of personalized medicine and increased prevalence of chronic conditions have spurred demand for therapeutic alternatives that are both effective and affordable. Amid an ecosystem that now necessitates swift responses to emergent healthcare challenges, the industry has seen a decisive shift towards patient-centric approaches. In tandem with these trends, the deployment of data analytics and advanced market research techniques has enabled companies to gain real-time insights into consumer behavior and demand patterns, thereby refining their strategic initiatives.

The ongoing transformation is clearly multifaceted and far-reaching. It is driven by the need not only to cater to the cost sensitivities of populations but also to address a broader spectrum of therapeutic requirements. Consequently, companies are pivoting from traditional, volume-based operational models to more innovative, quality-focused paradigms. This evolution underscores a broader trend wherein the integration of advanced technologies with robust regulatory support is setting a new benchmark for performance and innovation in the generic drugs market.

Key Segmentation Insights in the Generic Drugs Market

A thorough segmentation analysis offers valuable perspectives on the drivers and barriers that are influencing the generic drugs market. First, when evaluating the product type, the market is analyzed by distinguishing between over-the-counter generic drugs and prescription generic drugs. This delineation enables market players to refine their approaches based on customer access dynamics and regulatory considerations. In addition to the dichotomy of product types, the evaluation extends to drug class, which encompasses an array of therapeutic substances such as analgesics, antibiotics, antidepressants, antidiabetics, antihistamines, and antihypertensives. These categories are of utmost importance as they reflect the core areas of focus in addressing prevalent health concerns across diverse populations.

Further segmentation explores the route of administration, which involves an intricate examination of inhalations, injectables, oral, and topical formulations. Each route serves a different clinical purpose and caters to distinct patient needs, with each modality presenting unique challenges in regulatory approval and market penetration. The detailed consideration of patient type-covering adult, geriatric, and pediatric demographics-further sharpens the strategic insights by highlighting the evolving treatment requirements across age groups. Such insights allow manufacturers and distributors to customize their offerings to meet specific demographic needs.

Moreover, therapeutic application plays a critical role in segmentation as the market is observed through categories including anti-infectives, cardiovascular, central nervous system (CNS) drugs, diabetes, oncology, and respiratory treatments. A deep understanding of these therapeutic areas not only emphasizes product differentiation but also enhances the relevance of market strategies. Lastly, distribution channels are scrutinized by distinguishing between offline and online pharmacies. The offline segment further bifurcates into hospital pharmacies and retail pharmacies, each with its operational nuances and market dynamics. This layered approach to segmentation helps in identifying growth drivers and potential pockets of opportunity that can be strategically targeted.

Through this comprehensive segmentation, industry stakeholders can gain a clearer understanding of consumer behavior, regulatory challenges, and the competitive environment. The analysis underscores that a multi-dimensional segmentation strategy is essential for aligning product development, market entry, and distribution strategies with the evolving market demands in the generic drugs sector.

Based on Product Type, market is studied across Over-the-Counter (OTC) Generic Drugs and Prescription Generic Drugs.

Based on Drug Class, market is studied across Analgesics, Antibiotics, Antidepressants, Antidiabetics, Antihistamines, and Antihypertensives.

Based on Route of Administration, market is studied across Inhalations, Injectables, Oral, and Topical.

Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.

Based on Therapeutic Application, market is studied across Anti-infectives, Cardiovascular, Central Nervous System (CNS), Diabetes, Oncology, and Respiratory.

Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.

Regional Trends Shaping Generic Drugs Dynamics

Analysis of the market by region offers granular insights into the diverse challenges and opportunities inherent in the generic drugs industry. Distinct trends in the Americas have showcased an aggressive push towards the adoption of cost-effective medications, driven by both policy support and robust healthcare infrastructure. The region has consistently demonstrated a high level of consumer trust in generic alternatives, and market strategies in this area are focused on innovation, quality assurance, and competitive pricing mechanisms.

In the Europe, Middle East & Africa region, market dynamics have been shaped by a balance between historical regulatory frameworks and rapidly emerging technological trends. Although the regulatory environment remains stringent, continuous efforts towards streamlining approval processes have fostered growth. The diversity in economic development and healthcare infrastructure across these areas necessitates a tailored approach, where strategies are adapted not only to meet regulatory compliances but also to address the diverse economic challenges of the region.

Similarly, the Asia-Pacific region has emerged as a significant growth driver in the global generic drugs market. Rapid urbanization, increased healthcare expenditures, and an upsurge in awareness about affordable pharmacotherapies have collectively fueled market growth. The region's unique ability to leverage economies of scale, coupled with an expanding pool of research and innovation, is transforming it into a powerhouse of generic drug manufacturing and distribution. Such regional disparities and growth patterns provide a comprehensive understanding of where the opportunities and challenges lie in different geographical terrains.

Collectively, these regional insights are pivotal for companies seeking to tailor their strategic initiatives. By leveraging detailed regional analysis, market leaders can develop targeted strategies that account for economic, cultural, and regulatory nuances, thereby optimizing their market penetration efforts and ensuring long-term sustainability.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving the Market Momentum

A competitive analysis of the market reveals a robust lineup of companies that have emerged as key players, driving innovation, quality, and market expansion in the generic drugs space. Industry leaders such as Abbott Laboratories, Alembic Pharmaceuticals Limited, and Alkem Laboratories Limited set high benchmarks through rigorous quality control measures and strategic outreach. Firms like Amneal Pharmaceuticals, Inc. and Aspen Pharmacare Holdings Limited have consistently invested in research and development to secure a competitive edge, adapting swiftly to market changes and regulatory requirements.

Furthermore, companies including Aurobindo Pharma Limited, Bausch Health Companies Inc., and Baxter International Inc. have leveraged advanced manufacturing processes to deliver cost-effective therapeutics without compromising on quality. These organizations continuously refine their product portfolios to cater to an increasingly demanding market base that spans varied therapeutic classes and patient segments. Industry titans such as Biocon Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., and Eli Lilly and Company have pooled their expertise to navigate complex market dynamics, ensuring that innovative yet affordable therapeutic solutions remain accessible to diverse populations.

In addition, the presence of major entities like Endo, Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Limited highlights the market's intensive focus on quality and strategic partnerships. These companies have been instrumental in championing advancements across drug classes including central nervous system (CNS) therapies and chronic disease management solutions. Notably, forward-thinking players such as Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., and Krka, d. d. have embraced digitization and process optimization to further enhance their market position.

The role of global powerhouses such as Lupin Limited, Pfizer, Inc., Sandoz Group AG, Sanofi SA, and STADA Arzneimittel AG is equally significant as they expand their generic drug portfolios to incorporate breakthrough therapies. The competitive dynamics are further enriched by the sustained efforts of Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Limited, who continue to enhance market accessibility and affordability. This competitive landscape drives all players to continuously innovate and evolve, ultimately shaping the market's trajectory in significant ways.

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Amneal Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International Inc., Biocon Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo, Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC., Intas Pharmaceuticals Ltd., Krka, d. d., Lupin Limited, Pfizer, Inc., Sandoz Group AG, Sanofi SA, STADA Arzneimittel AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Limited. Strategic Recommendations for Market Stakeholders

For industry leaders aiming to consolidate their market position and capitalize on emerging opportunities, several strategic recommendations emerge from the comprehensive analysis. Firstly, a deep commitment to research and development is essential. Investing in advanced manufacturing technologies, fostering innovation in drug formulations, and streamlining production processes can result in significant competitive advantages, ensuring that generic drugs remain safe, effective, and affordable.

Secondly, establishing robust strategic partnerships is key. Collaborations with technology providers, research institutions, and key opinion leaders can facilitate access to cutting-edge insights and capabilities. This collaborative approach enables companies to quickly adapt to shifting market dynamics and regulatory requirements, thereby enhancing time-to-market for generics that address critical therapeutic needs.

Further, market stakeholders need to place an emphasis on segmentation-driven strategies. By leveraging robust segmentation models that encompass product types, drug classes, routes of administration, patient types, therapeutic applications, and distribution channels, companies can devise targeted strategies that resonate with specific consumer needs. Such stratified approaches allow for the optimization of resources and the tailoring of marketing initiatives, ensuring that the right product is available to the right patient at the right time.

Another recommendation is to adopt data-driven decision-making frameworks. Harnessing advanced analytics and market intelligence can provide real-time insights that inform strategic planning and operational execution. This can lead to better demand forecasting, improved inventory management, and more effective pricing strategies that align with market dynamics in various regions.

Finally, companies should focus on regulatory agility and an adaptive approach to compliance. In a market that is subject to diverse and evolving regulatory conditions across geographies, maintaining compliance while ensuring innovation is a delicate balancing act. Proactive engagement with regulatory bodies and continuous monitoring of policy changes will help manufacturers to swiftly adapt and maintain market credibility. These actionable steps, when combined with a long-term strategic vision, can empower market leaders to not only navigate current challenges but also to spearhead future innovations in the generic drugs landscape.

Concluding Strategic Insights in the Generic Drugs Market

In summary, the generic drugs market is poised at a pivotal crossroad underscored by rapid technological advancements, evolving regulatory frameworks, and a clear shift towards patient-centric therapeutic solutions. The comprehensive analysis presented here underscores a fervent movement away from traditional operational models, making way for innovative approaches that emphasize quality, efficiency, and strategic segmentation. By understanding the intricacies of market dynamics-from robust regional trends to the competitive maneuvers of industry frontrunners-stakeholders can chart a clearer path to sustained growth and market relevance.

The journey ahead is marked by both challenges and vast opportunities. Success in this market will depend on the ability to adapt to rapid changes, leverage data-driven insights, and forge strategic partnerships that drive innovation. Ultimately, embracing these insights will not only help in navigating today's complexities but also in shaping a resilient and forward-looking framework for the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Favorable government initiatives promoting the use of generic drugs to reduce healthcare expenditure
      • 5.1.1.2. Increasing investments in biosimilar development driving growth in the generic drugs market
      • 5.1.1.3. Rising prevalence of chronic diseases propels demand for affordable and accessible medications
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over the quality, efficacy, and safety of generic drugs impacting their adoption
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent expirations of drugs creating significant opportunities for the launch of generic alternatives
      • 5.1.3.2. Innovations in drug manufacturing processes to reduce costs and improve the quality of generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval timelines posing challenges for generic drug manufacturers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing need for over-the-counter (OTC) generic drugs due to high consumer accessibility and affordability
    • 5.2.2. Drug Class: Rising usage of antidepressants to enhance patient adherence and therapeutic outcomes
    • 5.2.3. Route of Administration: Utilization of oral route due to its convenience and widespread patient acceptance
    • 5.2.4. Patient Type: Utilization of generic drugs in geriatric type for tablets and liquid formulations
    • 5.2.5. Therapeutic Application: Adaoption of diabetes generic drug in oral hypoglycemics and insulin
    • 5.2.6. Distribution Channel: Growing preference for offline distribution channels due to convenience and personalized service
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Drugs Market, by Product Type

  • 6.1. Introduction
  • 6.2. Over-the-Counter (OTC) Generic Drugs
  • 6.3. Prescription Generic Drugs

7. Generic Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Analgesics
  • 7.3. Antibiotics
  • 7.4. Antidepressants
  • 7.5. Antidiabetics
  • 7.6. Antihistamines
  • 7.7. Antihypertensives

8. Generic Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Injectables
  • 8.4. Oral
  • 8.5. Topical

9. Generic Drugs Market, by Patient Type

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Generic Drugs Market, by Therapeutic Application

  • 10.1. Introduction
  • 10.2. Anti-infectives
  • 10.3. Cardiovascular
  • 10.4. Central Nervous System (CNS)
  • 10.5. Diabetes
  • 10.6. Oncology
  • 10.7. Respiratory

11. Generic Drugs Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Generic Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Hikma launches generic liraglutide injection after FDA approval
    • 15.3.2. FDA approves generic Nilotinib for chronic myeloid leukemia
    • 15.3.3. BC partners majority stake in generics leader Synthon to Goldman Sachs alternatives
    • 15.3.4. Penn Medicine collaborates with Mark Cuban's Cost Plus Drugs to enhance generic drug accessibility
    • 15.3.5. Glenmark expands its ophthalmic portfolio with the launch of travoprost, a cost-effective glaucoma treatment
    • 15.3.6. Sunshine Biopharma expands Canadian market presence with ursodiol launch
    • 15.3.7. Gilead partners with global generic drugmakers to enhance affordable HIV treatment accessibility
    • 15.3.8. Platinum Equity acquires major stake in Inventia Healthcare to bolster global generics presence
    • 15.3.9. Cipla secures final approval for generic drug version
    • 15.3.10. Zydus Lifesciences enters US market with generic overactive bladder medication
    • 15.3.11. ChrysCapital's strategic investment in La Renon aims to strengthen its position in the generic drug market
    • 15.3.12. Cosmos Health strengthens position in generics market with strategic acquisition
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Cipla Limited
    • 15.4.2. Teva Pharmaceutical Industries Ltd.
    • 15.4.3. Abbott Laboratories
    • 15.4.4. Sun Pharmaceutical Industries Limited

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alembic Pharmaceuticals Limited
  • 3. Alkem Laboratories Limited
  • 4. Amneal Pharmaceuticals, Inc.
  • 5. Aspen Pharmacare Holdings Limited
  • 6. Aurobindo Pharma Limited
  • 7. Bausch Health Companies Inc.
  • 8. Baxter International Inc.
  • 9. Biocon Limited
  • 10. Cipla Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. Endo, Inc.
  • 14. Fresenius SE & Co. KGaA
  • 15. GlaxoSmithKline PLC
  • 16. Glenmark Pharmaceuticals Limited
  • 17. Hikma Pharmaceuticals PLC.
  • 18. Intas Pharmaceuticals Ltd.
  • 19. Krka, d. d.
  • 20. Lupin Limited
  • 21. Pfizer, Inc.
  • 22. Sandoz Group AG
  • 23. Sanofi SA
  • 24. STADA Arzneimittel AG
  • 25. Sun Pharmaceutical Industries Limited
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viatris Inc.
  • 28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. GENERIC DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. GENERIC DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 330. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 331. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024